Eclipse Medical Information

Eclipse Medical is a structural heart medical device company advancing next-generation therapies to reduce stroke risk in patients with atrial fibrillation. Our flagship technology, the Omega™ Left Atrial Appendage (LAA) Occluder, is engineered for more effective closure, enhanced stability, and simplified implantation addressing a critical unmet need in percutaneous LAA closure. The Omega LAA Occluder features a unique cup-and-disc design constructed from a nitinol micromesh that provides self-centring apposition, secure anchoring, and reliable sealing of the left atrial appendage, offering a potential alternative to long-term anticoagulation for patients with non-valvular atrial fibrillation. Eclipse Medical is committed to rigorous clinical evaluation and real-world evidence generation to demonstrate safety and performance. The Omega device has been evaluated in early studies and is the subject of ongoing clinical research to expand its clinical utility. Key Highlights: • Structural heart technology focused on stroke prevention in atrial fibrillation patients. • Proprietary LAA occlusion device designed for procedural simplicity, conformability, and improved anatomic fit. • Clinical research and first-in-human evidence support procedural success and effective occlusion. • Based in Dublin, Ireland, with global distribution strategy and a growing evidence base. We are actively engaging with strategic partners, clinicians, and investors to bring transformational cardiovascular technology to market and improve outcomes for patients worldwide.